Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SYRE
stocks logo

SYRE

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.711
-17.31%
--
--
-0.769
-43.46%
--
--
-0.842
+3.98%
Estimates Revision
The market is revising No Change the revenue expectations for Spyre Therapeutics, Inc. (SYRE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 15.40%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-14.26%
In Past 3 Month
Stock Price
Go Up
up Image
+15.40%
In Past 3 Month
9 Analyst Rating
up Image0
Wall Street analysts forecast SYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYRE is 59.20 USD with a low forecast of 40.00 USD and a high forecast of 71.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
up Image0
Current: 16.260
sliders
Low
40.00
Averages
59.20
High
71.00
up Image0
Current: 16.260
sliders
Low
40.00
Averages
59.20
High
71.00
Leerink Partners
Faisal Khurshid
Buy
Initiates
$45
2025-04-08
Reason
Leerink Partners
Faisal Khurshid
Price Target
$45
2025-04-08
Initiates
Buy
Reason
Jones Trading
Debanjana Chatterjee
Hold
Initiates
n/a
2024-12-11
Reason
Jones Trading
Debanjana Chatterjee
Price Target
n/a
2024-12-11
Initiates
Hold
Reason
Baird
Colleen Kusy
Buy
Maintains
$50 → $65
2024-11-13
Reason
Baird
Colleen Kusy
Price Target
$50 → $65
2024-11-13
Maintains
Buy
Reason
Baird raised the firm's price target on Spyre Therapeutics to $65 from $50 and keeps an Outperform rating on the shares. The firm said they posted better-than-expected initial data from SPY001 and thinks the data incrementally de-risks its lead asset and broad pipeline, which could offer best-in-class dosing and potentially improved efficacy in IBD.
Guggenheim
Yatin Suneja
Strong Buy
Maintains
$50 → $65
2024-10-25
Reason
Guggenheim
Yatin Suneja
Price Target
$50 → $65
2024-10-25
Maintains
Strong Buy
Reason
Wedbush
David Nierengarten
Buy
Initiates
$45
2024-09-04
Reason
Wedbush
David Nierengarten
Price Target
$45
2024-09-04
Initiates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Spyre Therapeutics Inc (SYRE.O) is -5.37, compared to its 5-year average forward P/E of -4.86. For a more detailed relative valuation and DCF analysis to assess Spyre Therapeutics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.86
Current PE
-5.37
Overvalued PE
-1.78
Undervalued PE
-7.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.07
Current EV/EBITDA
-2.81
Overvalued EV/EBITDA
0.64
Undervalued EV/EBITDA
-4.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
165.25
Current PS
0.00
Overvalued PS
548.83
Undervalued PS
-218.33

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders areSelling! The selling amount has increased 2153.76% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 2153.76% over the last month.
Sold
Bought

SYRE News & Events

Events Timeline

(ET)
2025-06-17
07:33:49
Spyre Therapeutics reports positive interim Phase 1 results for TL1A antibodies
select
2025-05-08 (ET)
2025-05-08
16:18:31
Spyre Therapeutics reports Q1 EPS (60c), consensus (84c)
select
2025-05-05 (ET)
2025-05-05
08:14:09
Spyre Therapeutics' SPY001 shows efficacy in two poster presentations
select
Sign Up For More Events
Sign Up For More Events

News

Preview
5.0
08-02Newsfilter
Spyre Therapeutics Announces Grants of Inducement Awards

  • Stock Options Granted: Spyre Therapeutics approved the grant of stock options for 60,400 shares to five non-executive employees as part of their equity inducement awards under the 2018 Equity Inducement Plan, with an exercise price of $16.26 and a 10-year term.

  • Company Overview: Spyre Therapeutics is focused on developing innovative treatments for inflammatory bowel disease (IBD) and other immune-mediated diseases through advanced antibody engineering and therapeutic combinations.

Preview
8.0
07-04Newsfilter
Spyre Therapeutics Announces Grants of Inducement Awards

  • Stock Options Granted: Spyre Therapeutics approved stock options for four non-executive employees, totaling 121,600 shares, as part of their 2018 Equity Inducement Plan, with an exercise price of $15.49 per share.

  • Company Overview: Spyre Therapeutics is focused on developing innovative treatments for inflammatory bowel disease (IBD) and other immune-mediated diseases through advanced antibody engineering and therapeutic combinations.

Preview
9.0
06-17Newsfilter
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

  • Phase 1 Trial Results: Spyre Therapeutics announced positive interim results from Phase 1 trials of its investigational antibodies SPY002 and SPY072, demonstrating good tolerability, a prolonged half-life of approximately 75 days, and effective suppression of TL1A, supporting their advancement into Phase 2 clinical trials for ulcerative colitis and rheumatologic diseases.

  • Upcoming Clinical Trials: The company has initiated the SKYLINE-UC platform trial for ulcerative colitis and plans to start the SKYWAY-RD basket trial for rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis in Q3 2025, with multiple proof-of-concept data readouts expected between 2026 and 2027.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Spyre Therapeutics Inc (SYRE) stock price today?

The current price of SYRE is 16.26 USD — it has decreased -4.18 % in the last trading day.

arrow icon

What is Spyre Therapeutics Inc (SYRE)'s business?

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.

arrow icon

What is the price predicton of SYRE Stock?

Wall Street analysts forecast SYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYRE is 59.20 USD with a low forecast of 40.00 USD and a high forecast of 71.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Spyre Therapeutics Inc (SYRE)'s revenue for the last quarter?

Spyre Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Spyre Therapeutics Inc (SYRE)'s earnings per share (EPS) for the last quarter?

Spyre Therapeutics Inc. EPS for the last quarter amounts to -0.74 USD, decreased -38.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Spyre Therapeutics Inc (SYRE)'s fundamentals?

The market is revising No Change the revenue expectations for Spyre Therapeutics, Inc. (SYRE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 15.40%.
arrow icon

How many employees does Spyre Therapeutics Inc (SYRE). have?

Spyre Therapeutics Inc (SYRE) has 65 emplpoyees as of August 03 2025.

arrow icon

What is Spyre Therapeutics Inc (SYRE) market cap?

Today SYRE has the market capitalization of 981.35M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free